Catching pathway interactions early saves money and lives.
In the long effort to understand not just what drugs do but how they do it, INDIGO Biosciences has added a new instrument to the researcher's toolkit — one that watches not for what a compound awakens, but for what it silences. By offering cell-based assays that capture the cross-talk between glucocorticoid receptor signaling and NF-κB-driven inflammation, the company addresses a persistent blind spot in early drug characterization. The stakes are familiar: promising compounds that look clean in activation studies have a way of revealing hidden liabilities only after considerable investment, and the ability to see those interactions earlier is, in the language of science, a form of wisdom.
- Off-target pathway interactions have quietly derailed promising drug candidates for decades, and the pressure to catch them earlier has never been greater.
- INDIGO's new Transrepression Assay Services target a specific and consequential biological conversation — the moment when glucocorticoid receptor signaling steps in to suppress the inflammatory genes that NF-κB would otherwise drive.
- The launch fills a directional gap: where existing assays measured what compounds switch on, this service measures what they switch off, and whether that suppression is selective or dangerously broad.
- Potency, efficacy, and dose-response data are now available within this transrepression framework, paired with scientific support for study design and mechanistic interpretation.
- The service lands as a practical decision-making tool — helping research teams determine earlier whether a compound carries genuine therapeutic promise or hidden developmental risk.
INDIGO Biosciences announced this week a new service designed to address a specific and consequential gap in drug discovery: the ability to observe not what a compound activates, but what it suppresses — and how that suppression ripples across interconnected signaling pathways.
The new Transrepression Assay Services center on the cross-talk between glucocorticoid receptor signaling and NF-κB-driven transcriptional activity. Transrepression itself is a biological mechanism in which one transcription factor actively silences another through pathway interference, reducing downstream gene expression. In the glucocorticoid and NF-κB context, this is more than academic: much of the anti-inflammatory power of glucocorticoids comes not from activating their own gene targets, but from quieting the inflammatory genes NF-κB would otherwise drive. A compound that achieves this selectively could offer meaningful therapeutic benefit with fewer systemic side effects.
The service complements INDIGO's existing receptor activation and reporter assay portfolio, extending the company's analytical reach from what compounds turn on to what they turn off. Researchers gain access to potency, efficacy, and dose-response analysis within this framework, along with scientific guidance on study design and mechanistic interpretation.
Dr. Andrew Woodman, Laboratory Director at INDIGO Biosciences, described the expansion as a natural deepening of the company's commitment to complete compound characterization — enabling customers to probe pathway-selective activity and surface the kind of mechanistic insight that shapes go or no-go decisions in development.
As drug discovery has grown more sophisticated, the demand to understand not just a compound's primary action but its broader pathway behavior has intensified. Tools that surface hidden interactions early — before they become costly late-stage failures — represent exactly the kind of foresight the field increasingly requires.
INDIGO Biosciences announced a new service this week that fills a specific gap in how drug researchers test compounds. The company, which already runs cell-based assays to measure how drugs activate receptors and pathways, is now offering something narrower and more mechanistically precise: the ability to watch what happens when one transcription factor actively suppresses another.
The new Transrepression Assay Services focus on a particular interaction—the cross-talk between glucocorticoid receptor signaling and NF-κB-driven transcriptional activity. In plain terms, this means researchers can now test compounds in a controlled lab setting to see whether a drug designed to hit one pathway inadvertently dampens activity in another. That kind of pathway selectivity matters enormously in drug development, especially for anti-inflammatory compounds, where the goal is often to suppress inflammatory signals without triggering unwanted side effects elsewhere in the cell.
Transrepression itself is a biological mechanism worth understanding. It occurs when one transcription factor—a protein that controls which genes get turned on or off—actively silences another transcription factor through signaling pathway cross-talk. The result is reduced gene expression downstream. In the context of glucocorticoid receptor and NF-κB interaction, this becomes functionally important: glucocorticoids are powerful anti-inflammatory agents, and much of their effect comes not from activating their own genes but from suppressing the inflammatory genes that NF-κB would normally drive. A compound that can achieve this transrepression selectively might offer therapeutic benefit with fewer side effects than a drug that simply floods the system with glucocorticoid activity.
The service complements INDIGO's existing portfolio of receptor activation and pathway reporter assays. Where those earlier tools measured what a compound turns on, the new transrepression assays measure what it turns off—and crucially, how one pathway's suppression affects another. The company now provides potency, efficacy, and dose-response analysis within this framework, along with scientific support for study design, data interpretation, and the mechanistic reasoning that follows.
Dr. Andrew Woodman, Laboratory Director at INDIGO Biosciences, framed the expansion as a natural extension of the company's mission to give researchers more complete tools for compound characterization. The addition of GR/NF-κB transrepression studies, he noted, allows customers to investigate pathway-selective activity more deeply and generate the kind of mechanistic insight that informs whether a compound is worth advancing or whether it carries hidden liabilities.
The service is positioned for several research contexts: anti-inflammatory drug discovery programs, glucocorticoid receptor research, nuclear receptor pharmacology more broadly, and any study where understanding signaling pathway modulation matters. As drug discovery has matured, the pressure to understand not just what a compound does but how it does it—and what else it might be doing—has intensified. Off-target effects and unexpected pathway interactions have derailed many otherwise promising compounds late in development. A tool that lets researchers catch those interactions earlier, in a controlled assay format, potentially saves time and money downstream.
With this launch, INDIGO is betting that drug discovery teams will value the ability to profile compounds not just for activation but for selective suppression, and that the mechanistic clarity this provides will translate into better decision-making across research and development programs.
Notable Quotes
Expanding our service capabilities to include transrepression assays reflects INDIGO's ongoing commitment to providing researchers with biologically relevant tools for more complete compound characterization.— Dr. Andrew Woodman, Laboratory Director, INDIGO Biosciences
The Hearth Conversation Another angle on the story
What exactly is transrepression, and why does it matter more now than it did five years ago?
It's one transcription factor actively silencing another through pathway cross-talk. It matters now because we've learned the hard way that compounds don't act in isolation—they ripple across multiple pathways. A drug that suppresses inflammation through one mechanism might inadvertently suppress something else you didn't want suppressed. Catching that early saves money and lives.
So this is really about de-risking compounds before they go into the clinic?
Exactly. You can test a compound's selectivity in a dish before you invest in animal studies or human trials. If it looks clean in the transrepression assay, you have more confidence. If it doesn't, you know you have a problem to solve.
Why focus on GR and NF-κB specifically?
Because that interaction is central to how anti-inflammatory drugs actually work. Glucocorticoids are some of the most powerful anti-inflammatory agents we have, and a lot of their effect comes from suppressing NF-κB-driven inflammation. If you're designing a new anti-inflammatory, understanding how your compound affects that specific cross-talk is essential.
Does this mean INDIGO is positioning itself as the company that understands pathway selectivity?
That's part of it. They're saying: we don't just measure what your compound turns on. We measure what it turns off, and how those two things interact. That's a more complete picture of what a drug actually does in a cell.
Who benefits most from this service?
Drug discovery teams working on inflammation, nuclear receptors, and anything where you need to know not just potency but selectivity. It's most valuable early in discovery, when you're still deciding which compounds to advance.